Talecris Biotherapeutics Holdings Corp. (“Talecris”) today announced the launch of its initial public offering of 44,736,842 shares of its common stock, par value $0.01 per share. Talecris is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, neurology, pulmonology and hemostasis.
Of the shares being offered, 28,947,368 are being offered by Talecris and 15,789,474 are being offered by the selling stockholder, Talecris Holdings, LLC. Talecris Holdings, LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and limited partnerships affiliated with Ampersand Ventures. The initial public offering price is expected to be between $18.00 and $20.00 per share. Talecris has applied to have the shares of common stock approved for quotation on The Nasdaq Global Market under the ticker symbol “TLCR.” The underwriters have the option to purchase from the selling stockholder up to an additional 6,710,526 shares of common stock, on the same terms and conditions.
Talecris intends to use the net proceeds of the offering to repay amounts owed under its First Lien Term Loan Credit Agreement and Second Lien Term Loan Credit Agreement. Talecris will not receive any of the proceeds from the offering of the common stock by the selling stockholder.
Morgan Stanley, Goldman, Sachs & Co., Citigroup Global Markets Inc. and J.P. Morgan Securities Inc. are acting as joint book-running managers for the proposed offering. Wells Fargo Securities, LLC, Barclays Capital Inc. and UBS Investment Bank are acting as co-managers.